Literature DB >> 22866152

The optimal age for performing surgery on patients with MEN 2B syndrome.

C Gómez I Gavara1, J L Ponce Marco, T Belda Ibañez, A Boscà Robledo, C Sebastian Pastor, R Navarro Milla, M Caballero Soto, M Meseguer Anastasio.   

Abstract

Multiple endocrine neoplasia (MEN) syndromes are characterized by the association of various endocrine neoplasias. Prophylactic thyroidectomy is the treatment of choice for patients with RET gene mutations. The age at which patients undergo prophylactic thyroidectomy may vary depending on the position of the RET gene codon. In cases of MEN 2B, when the mutation is carried in codons 883, 918 or 922, prophylactic thyroidectomy is performed prior to 6 months of age, due to the increased aggressiveness of these heterozygosities, which are capable of determining the onset of medullary cancer during the first months of life. We present two heterozygous twin patients with MEN 2B syndrome who were born 32 weeks premature, and who underwent prophylactic thyroidectomy at 7 months of age. The patients were carriers of the mutation at codon 918. We suggested the early surgery at 7 months as, due to their prematurity, the patients were required to gain weight to improve their condition prior to surgery. The two patients had medullary thyroid carcinoma without lymph node involvement. In conclusion, for a truly prophylactic thyroidectomy, such patients should undergo surgery within the first month of life, particularly if these patients are carriers of the mutation in codons 883, 918 or 922.

Entities:  

Year:  2011        PMID: 22866152      PMCID: PMC3408057          DOI: 10.3892/ol.2011.332

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  4 in total

Review 1.  Guidelines for diagnosis and therapy of MEN type 1 and type 2.

Authors:  M L Brandi; R F Gagel; A Angeli; J P Bilezikian; P Beck-Peccoz; C Bordi; B Conte-Devolx; A Falchetti; R G Gheri; A Libroia; C J Lips; G Lombardi; M Mannelli; F Pacini; B A Ponder; F Raue; B Skogseid; G Tamburrano; R V Thakker; N W Thompson; P Tomassetti; F Tonelli; S A Wells; S J Marx
Journal:  J Clin Endocrinol Metab       Date:  2001-12       Impact factor: 5.958

2.  The natural course of multiple endocrine neoplasia type IIb. A study of 18 cases.

Authors:  H F Vasen; M van der Feltz; F Raue; A N Kruseman; H P Koppeschaar; G Pieters; F J Seif; W F Blum; C J Lips
Journal:  Arch Intern Med       Date:  1992-06

3.  Medullary thyroid carcinoma in multiple endocrine neoplasia types 2A and 2B.

Authors:  D S O'Riordain; T O'Brien; A L Weaver; H Gharib; I D Hay; C S Grant; J A van Heerden
Journal:  Surgery       Date:  1994-12       Impact factor: 3.982

Review 4.  Medullary thyroid cancer: management guidelines of the American Thyroid Association.

Authors:  Richard T Kloos; Charis Eng; Douglas B Evans; Gary L Francis; Robert F Gagel; Hossein Gharib; Jeffrey F Moley; Furio Pacini; Matthew D Ringel; Martin Schlumberger; Samuel A Wells
Journal:  Thyroid       Date:  2009-06       Impact factor: 6.568

  4 in total
  1 in total

1.  Epidemiology, clinical features, and genetics of multiple endocrine neoplasia type 2B in a complete population.

Authors:  Anna Znaczko; Deirdre E Donnelly; Patrick J Morrison
Journal:  Oncologist       Date:  2014-10-29
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.